Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 TrialM Hasib Sidiqi, Kwee Yong, Carolyn C. Jackson et al.|Transplantation and Cellular Therapy|2024Cited by 1